Mediwound Ltd Ord Sh (MDWD) Stock Price, Quote & News

Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic ther...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 797 14100

Website: www.mediwound.com

Address:

42 Hayarkon Street, Yavne, Israel

novelty May. 13 at 1:16 PM

$MDWD how is following Zee contrarians failed pump? Hahahha

0 · Reply

novelty May. 13 at 1:06 PM

$MDWD management must just love there shitco

0 · Reply

novelty May. 13 at 12:57 PM

$MDWD gap N go this morning drive her right through 13$ like butter. She’s done. Never to see another up day ever again. Hahahah feel bad for the suckers here

0 · Reply

novelty May. 13 at 12:53 PM

$MDWD SHITCO

0 · Reply

novelty May. 13 at 12:41 PM

$MDWD after hours 14$!!!!!

0 · Reply

novelty May. 13 at 12:36 PM

$MDWD imagine being a sucker and actually buying this SHITCO

0 · Reply

novelty May. 13 at 12:30 PM

$MDWD SOOOO BAD

0 · Reply

novelty May. 13 at 12:28 PM

$MDWD if u own israeli companies ur an idiot

0 · Reply

novelty May. 13 at 12:27 PM

$MDWD 15$ stonk bout to be turned into 9$ stonk. Ha Ha Ha Ha

0 · Reply

novelty May. 12 at 2:03 PM

$MDWD big red sticks only

0 · Reply

MediWound to Report First Quarter 2026 Financial Results

Apr 13, 2026, 7:30 AM EDT - 4 weeks ago

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

Apr 7, 2026, 7:00 AM EDT - 5 weeks ago

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

2026-04-02T19:37:47.000Z - 5 weeks ago

MediWound says Vericel awarded ten-year contract valued at up to $197M

VCEL

Apr 2, 2026, 3:26 PM EDT - 5 weeks ago

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

2026-03-12T16:05:24.000Z - 2 months ago

MediWound management to meet with Maxim

Mar 5, 2026, 4:30 PM EST - 2 months ago

MediWound Files Annual Report on Form 20-F

Mar 5, 2026, 8:30 AM EST - 2 months ago

MediWound Earnings Call Transcript: Q4 2025

2026-03-05T12:15:32.000Z - 2 months ago

MediWound reports Q4 EPS (56c), consensus (61c)

2026-03-05T12:14:40.000Z - 2 months ago

MediWound sees FY26 revenue $24M-$26M, consensus $26.21M

2026-03-05T12:14:25.000Z - 2 months ago

MediWound sees FY27 revenue $32M-$35M, sees FY28 revenue $50M-$55M

Mar 5, 2026, 7:00 AM EST - 2 months ago

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-03T15:01:53.000Z - 2 months ago

MediWound management to meet with Maxim

Mar 2, 2026, 1:10 PM EST - 2 months ago

MediWound Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 10:40 AM EST - 2 months ago

MediWound Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 8:00 AM EST - 2 months ago

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 17, 2026, 8:00 AM EST - 3 months ago

MediWound to Present at Upcoming Investor Conferences

2026-01-12T12:06:19.000Z - 4 months ago

MediWound sees FY25 revenue $17M, consensus $22.98M

2026-01-12T12:05:27.000Z - 4 months ago

MediWound sees FY26 revenue $24-26M, consensus $28.8M

Jan 12, 2026, 7:00 AM EST - 4 months ago

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

2025-12-10T12:10:37.000Z - 5 months ago

MediWound reports clinical data on NexoBrid’s effectiveness

Dec 10, 2025, 7:00 AM EST - 5 months ago

MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

2025-11-21T11:10:36.000Z - 6 months ago

MediWound price target raised to $36 from $31 at H.C. Wainwright

Nov 20, 2025, 8:30 AM EST - 6 months ago

MediWound Earnings Call Transcript: Q3 2025

2025-11-20T12:06:10.000Z - 6 months ago

MediWound reports Q3 EPS (24c), consensus (98c)

Nov 20, 2025, 7:00 AM EST - 6 months ago

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:30 AM EST - 6 months ago

MediWound to Report Third Quarter 2025 Financial Results

2025-11-03T13:20:37.000Z - 6 months ago

MediWound completes commissioning of expanded GMP manufacturing facility

Nov 3, 2025, 8:00 AM EST - 6 months ago

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

2025-09-29T12:45:46.000Z - 8 months ago

MediWound announces $30M registered direct offering

2025-09-29T12:45:35.000Z - 8 months ago

MediWound down 8% at $16.50 following offering

Sep 29, 2025, 8:37 AM EDT - 8 months ago

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

2025-09-25T11:40:37.000Z - 8 months ago

MediWound announces marketing approval of NexoBrid in Australia

Sep 25, 2025, 7:30 AM EDT - 8 months ago

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

Sep 8, 2025, 4:30 PM EDT - 8 months ago

MediWound Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:30 AM EDT - 9 months ago

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

Aug 20, 2025, 7:30 AM EDT - 9 months ago

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:30 AM EDT - 9 months ago

MediWound Earnings Call Transcript: Q2 2025

2025-08-14T11:11:06.000Z - 9 months ago

MediWound reports Q2 EPS ($1.23), consensus (57c)

Aug 14, 2025, 7:00 AM EDT - 9 months ago

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-08-13T12:56:02.000Z - 9 months ago

MediWound announces EscharEx Phase II data

Aug 13, 2025, 8:45 AM EDT - 9 months ago

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

Aug 4, 2025, 7:30 AM EDT - 10 months ago

MediWound to Report Second Quarter 2025 Financial Results

2025-06-02T12:20:50.000Z - 1 year ago

MediWound assumed with an Outperform at Oppenheimer

2025-05-22T10:15:15.000Z - 1 year ago

MediWound price target raised to $31 from $25 at H.C. Wainwright

May 21, 2025, 8:30 AM EDT - 1 year ago

MediWound Earnings Call Transcript: Q1 2025

2025-05-21T11:05:30.000Z - 1 year ago

MediWound reports Q1 EPS (7c), consensus (66c)

May 21, 2025, 7:00 AM EDT - 1 year ago

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 7:30 AM EDT - 1 year ago

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 5, 2025, 8:00 AM EDT - 1 year ago

MediWound to Report First Quarter 2025 Financial Results

Mar 19, 2025, 8:30 AM EDT - 1 year ago

MediWound Earnings Call Transcript: Q4 2024

Mar 19, 2025, 7:00 AM EDT - 1 year ago

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 11:50 AM EST - 1 year ago

MediWound Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 8:00 AM EST - 1 year ago

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Feb 24, 2025, 8:00 AM EST - 1 year ago

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:12 AM EST - 1 year ago

MediWound to launch Phase III trial for venous leg ulcers

Feb 12, 2025, 8:00 AM EST - 1 year ago

MediWound Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Nov 26, 2024, 8:30 AM EST - 1 year ago

MediWound Earnings Call Transcript: Q3 2024

Nov 26, 2024, 7:00 AM EST - 1 year ago

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Oct 10, 2024, 7:00 AM EDT - 1 year ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Sep 10, 2024, 3:30 PM EDT - 1 year ago

MediWound Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 15, 2024, 4:15 PM EDT - 1 year ago

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Aug 14, 2024, 8:30 AM EDT - 1 year ago

MediWound Earnings Call Transcript: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

Aug 2, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report Second Quarter 2024 Financial Results

Jul 29, 2024, 8:00 AM EDT - 1 year ago

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Jul 16, 2024, 7:30 AM EDT - 1 year ago

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Jul 15, 2024, 7:32 AM EDT - 1 year ago

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Jul 15, 2024, 7:00 AM EDT - 1 year ago

MediWound Announces $25 Million Strategic Private Placement Financing

Jun 3, 2024, 10:34 AM EDT - 2 years ago

MediWound Earnings Call Transcript: Q1 2024

May 29, 2024, 7:00 AM EDT - 2 years ago

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 22, 2024, 8:00 AM EDT - 2 years ago

MediWound to Report First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 2 years ago

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MediWound Earnings Call Transcript: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 12, 2024, 7:00 AM EST - 2 years ago

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Feb 5, 2024, 8:00 AM EST - 2 years ago

MediWound to Participate in Two Upcoming Investor Conferences

Jan 9, 2024, 7:00 AM EST - 2 years ago

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

Dec 28, 2023, 7:00 AM EST - 2 years ago

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Dec 21, 2023, 8:00 AM EST - 2 years ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Nov 21, 2023, 8:30 AM EST - 2 years ago

MediWound Earnings Call Transcript: Q3 2023

Nov 21, 2023, 7:02 AM EST - 2 years ago

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

novelty May. 13 at 1:16 PM

$MDWD how is following Zee contrarians failed pump? Hahahha

0 · Reply

novelty May. 13 at 1:06 PM

$MDWD management must just love there shitco

0 · Reply

novelty May. 13 at 12:57 PM

$MDWD gap N go this morning drive her right through 13$ like butter. She’s done. Never to see another up day ever again. Hahahah feel bad for the suckers here

0 · Reply

novelty May. 13 at 12:53 PM

$MDWD SHITCO

0 · Reply

novelty May. 13 at 12:41 PM

$MDWD after hours 14$!!!!!

0 · Reply

novelty May. 13 at 12:36 PM

$MDWD imagine being a sucker and actually buying this SHITCO

0 · Reply

novelty May. 13 at 12:30 PM

$MDWD SOOOO BAD

0 · Reply

novelty May. 13 at 12:28 PM

$MDWD if u own israeli companies ur an idiot

0 · Reply

novelty May. 13 at 12:27 PM

$MDWD 15$ stonk bout to be turned into 9$ stonk. Ha Ha Ha Ha

0 · Reply

novelty May. 12 at 2:03 PM

$MDWD big red sticks only

0 · Reply

novelty May. 12 at 1:05 AM

$MDWD tmrw we revisit 15$

0 · Reply

novelty May. 11 at 7:58 PM

$MDWD good little pig close the lows

0 · Reply

novelty May. 11 at 3:35 PM

$MDWD big red candles is the way

0 · Reply

novelty May. 11 at 2:20 PM

$MDWD too Comical to watch this trade. Bids in at 12.99

0 · Reply

novelty May. 11 at 1:57 PM

$MDWD market maker has 12.99 programmed

0 · Reply

novelty May. 11 at 1:30 PM

$MDWD how does it feel to hold the worst stock On the market all year long? Hahahah

0 · Reply

novelty May. 8 at 4:01 PM

$MDWD 13$ stonk

0 · Reply

enalpa May. 8 at 3:26 PM

$MDWD WTF is the barrier to sales for this Product?

1 · Reply

z06forum May. 7 at 3:24 PM

$MDWD Vericell still reporting dismal Nexobrid sales in Q1 Due to delayed BARDA. Although normalizing the back half of the year I'm expecting 2026 Revenue forecast to be reduced by around 3.5M to 22.5 M from 25m. 2H 2026 should prove to align track. Expect a short term pullback to 15's after 5/27

1 · Reply

novelty May. 7 at 2:46 PM

$MDWD you didn’t really think we’d hold above 17 did you? 😂

0 · Reply

Estimize May. 7 at 12:03 PM

Wall St is expecting -0.64 EPS for $MDWD Q1 [Reporting 06/03 BMO] http://www.estimize.com/intro/mdwd?chart=historical&metric_name=eps&utm_c

0 · Reply

WallStWireAds May. 7 at 12:01 PM

$MDWD https://www.globenewswire.com/news-release/2026/05/07/3289907/30505/en/MediWound-to-Report-First-Quarter-2026-Financial-Results.html

0 · Reply

Market Cap	211.54M
Revenue (ttm)	16.96M
Net Income (ttm)	-23.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.80%
Debt to Equity Ratio	0.00

Volume	32,206
Avg Vol	84,254
Day's Range	N/A - N/A
Shares Out	12.85M
Stochastic %K	7%
Beta	0.21
Analysts	Strong Sell
Price Target	$31.33